About this data
What it is
The FDA publishes its decisions on drugs and medical devices through openFDA. We list approved drug applications and the changes approved to them, 510(k) clearances of devices and premarket approvals (PMA) of higher-risk devices, and match the applicant to a public company when the name lines up. The page opens on new brand-name drugs and biologics: the first approval of a new drug application (NDA) or biologics license application (BLA).
Who files it
The FDA decides; openFDA publishes the FDA's records. The applicant is the company named in the FDA's record for the application.
How current
We check openFDA every day. The FDA refreshes its files on its own schedule, and a decision can appear days to weeks after its date, so the latest approvals may show up late.
Terms
openFDAopenFDA is the FDA's public data service. It publishes the FDA's own records of drug approvals and device decisions. openFDA asks users not to imply that the FDA endorses their product or service: this site is not endorsed by or affiliated with the FDA.NDA and BLAA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original.supplementA later approved change to a drug that is already on the market: a new use, a new dose, a label change or a manufacturing change. Many supplements are minor.generic drugsA generic drug (an ANDA, or abbreviated new drug application) is approved because it matches a drug already on the market. Generics are made by many companies, most of which are not public.510(k)A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval.PMAPremarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.company matchWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.
Worth knowing
This is a record of decisions already made. It is not a calendar of coming decisions: a drug under review does not appear, and we show no review dates. openFDA asks users not to imply that the FDA endorses their product or service: this page is not endorsed by or affiliated with the FDA, and the FDA makes no warranty about the data. It is not for medical decisions. Most applicants, such as generic makers and private device makers, do not match a public company, and a subsidiary or a differently spelled name can be missed, so a row with no ticker may still belong to one. A clearance is not an approval, and many approved supplements are minor.
Not to be confused with
Clinical trial updates: what sponsors report about their studies, not what the FDA decided.

All of this comes from openFDA, the FDA's public data service. This site is not endorsed by or affiliated with the FDA.

FDA decisions per day, last 30 days

010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0
010203040Oct 17 · Brand-name drugs and biologics, with supplements: 0Oct 17 · Device clearances and approvals: 0Oct 17Oct 18 · Brand-name drugs and biologics, with supplements: 0Oct 18 · Device clearances and approvals: 1Oct 19 · Brand-name drugs and biologics, with supplements: 4Oct 19 · Device clearances and approvals: 10Oct 20 · Brand-name drugs and biologics, with supplements: 3Oct 20 · Device clearances and approvals: 12Oct 21 · Brand-name drugs and biologics, with supplements: 6Oct 21 · Device clearances and approvals: 18Oct 21Oct 22 · Brand-name drugs and biologics, with supplements: 6Oct 22 · Device clearances and approvals: 15Oct 23 · Brand-name drugs and biologics, with supplements: 7Oct 23 · Device clearances and approvals: 24Oct 24 · Brand-name drugs and biologics, with supplements: 0Oct 24 · Device clearances and approvals: 1Oct 25 · Brand-name drugs and biologics, with supplements: 0Oct 25 · Device clearances and approvals: 1Oct 25Oct 26 · Brand-name drugs and biologics, with supplements: 4Oct 26 · Device clearances and approvals: 17Oct 27 · Brand-name drugs and biologics, with supplements: 5Oct 27 · Device clearances and approvals: 18Oct 28 · Brand-name drugs and biologics, with supplements: 2Oct 28 · Device clearances and approvals: 15Oct 29 · Brand-name drugs and biologics, with supplements: 3Oct 29 · Device clearances and approvals: 27Oct 29Oct 30 · Brand-name drugs and biologics, with supplements: 6Oct 30 · Device clearances and approvals: 32Oct 31 · Brand-name drugs and biologics, with supplements: 0Oct 31 · Device clearances and approvals: 0Nov 1 · Brand-name drugs and biologics, with supplements: 0Nov 1 · Device clearances and approvals: 0Nov 2 · Brand-name drugs and biologics, with supplements: 1Nov 2 · Device clearances and approvals: 0Nov 2Nov 3 · Brand-name drugs and biologics, with supplements: 1Nov 3 · Device clearances and approvals: 0Nov 4 · Brand-name drugs and biologics, with supplements: 3Nov 4 · Device clearances and approvals: 0Nov 5 · Brand-name drugs and biologics, with supplements: 2Nov 5 · Device clearances and approvals: 0Nov 6 · Brand-name drugs and biologics, with supplements: 4Nov 6 · Device clearances and approvals: 0Nov 6Nov 7 · Brand-name drugs and biologics, with supplements: 0Nov 7 · Device clearances and approvals: 0Nov 8 · Brand-name drugs and biologics, with supplements: 0Nov 8 · Device clearances and approvals: 0Nov 9 · Brand-name drugs and biologics, with supplements: 5Nov 9 · Device clearances and approvals: 0Nov 10 · Brand-name drugs and biologics, with supplements: 5Nov 10 · Device clearances and approvals: 0Nov 10Nov 11 · Brand-name drugs and biologics, with supplements: 1Nov 11 · Device clearances and approvals: 0Nov 12 · Brand-name drugs and biologics, with supplements: 0Nov 12 · Device clearances and approvals: 0Nov 13 · Brand-name drugs and biologics, with supplements: 0Nov 13 · Device clearances and approvals: 0Nov 14 · Brand-name drugs and biologics, with supplements: 0Nov 14 · Device clearances and approvals: 0Nov 14Nov 15 · Brand-name drugs and biologics, with supplements: 0Nov 15 · Device clearances and approvals: 0

Brand-name drugs and biologics, with supplements Device clearances and approvals

By the FDA's decision date. Generic drugs are left out. The FDA's files can lag a decision by days to weeks, so the most recent days fill in later.

Latest FDA decisions

Reset

Showing: ticker GILD · Everything

Latest FDA decisions
DecidedProductApplicantWe match the applicant's name to a public company automatically, and by hand for the large drugmakers. Most applicants, such as generic makers and private device makers, do not match, and a subsidiary or a differently spelled name can be missed.DecisionA new drug application (NDA) asks the FDA to approve a drug made from chemicals. A biologics license application (BLA) asks for a biologic, such as an antibody or a vaccine. The first approval is the original. A device maker shows the FDA that its device is substantially equivalent to one already sold. The FDA clears it, which is a lighter review than an approval. Premarket approval: the FDA's strictest review, for higher-risk devices. The maker must show the device is safe and effective.FDA page
Aug 27, 2026BIXLENVO SUNLENCA STARTER PACK (COPACKAGED)
BICTEGRAVIR SODIUM, LENACAPAVIR SODIUM; LENACAPAVIR SODIUM
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Type 4 - New Combination
NDA221443 ↗
Aug 27, 2026BIXLENVO SUNLENCA STARTER PACK (COPACKAGED)
BICTEGRAVIR SODIUM, LENACAPAVIR SODIUM; LENACAPAVIR SODIUM
GILD
Gilead Sciences Inc
New drug (NDA)
Type 4 - New Combination
NDA221443 ↗
Aug 27, 2026BIXLENVO
BICTEGRAVIR SODIUM; LENACAPAVIR SODIUM
GILD
Gilead Sciences Inc
New drug (NDA)
Type 4 - New Combination
NDA221104 ↗
Aug 27, 2026SUNLENCA
LENACAPAVIR SODIUM
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Efficacy
NDA215974 ↗
Aug 27, 2026SUNLENCA
LENACAPAVIR SODIUM
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Efficacy
NDA215973 ↗
Jul 29, 2026VEKLURY
REMDESIVIR
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Labeling
NDA214787 ↗
Jun 24, 2026TRODELVY
SACITUZUMAB GOVITECAN-HZIY
GILD
Immunomedics Inc
Biologic (BLA), supplement
Efficacy
BLA761115 ↗
Jun 24, 2026TRODELVY
SACITUZUMAB GOVITECAN-HZIY
GILD
Immunomedics Inc
Biologic (BLA), supplement
Efficacy
BLA761115 ↗
May 22, 2026HEPCLUDEX
BULEVIRTIDE-GMOD
GILD
Gilead Sciences Inc
Biologic (BLA)
Type 1 - New Molecular Entity
BLA761468 ↗
May 21, 2026BIKTARVY
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FU…
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Manufacturing (CMC)
NDA210251 ↗
Mar 12, 2026SUNLENCA
LENACAPAVIR SODIUM
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Labeling
NDA215974 ↗
Mar 12, 2026SUNLENCA
LENACAPAVIR SODIUM
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Labeling
NDA215973 ↗
Jan 30, 2026LIVDELZI
SELADELPAR LYSINE
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Labeling
NDA217899 ↗
Oct 7, 2025VEKLURY
REMDESIVIR
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Labeling
NDA214787 ↗
Aug 22, 2025VEKLURY
REMDESIVIR
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Labeling
NDA214787 ↗
Jul 30, 2025BIKTARVY
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FU…
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Efficacy
NDA210251 ↗
Jun 20, 2025DESCOVY
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Efficacy
NDA208215 ↗
Jun 20, 2025DESCOVY
EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Efficacy
NDA208215 ↗
Jun 20, 2025TYBOST
COBICISTAT
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Efficacy
NDA203094 ↗
Jun 20, 2025TYBOST
COBICISTAT
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Efficacy
NDA203094 ↗
Jun 18, 2025YEZTUGO
LENACAPAVIR SODIUM
GILD
Gilead Sciences Inc
New drug (NDA)
Type 10 - New Indication Submitted as D…
NDA220020 ↗
Jun 18, 2025YEZTUGO
LENACAPAVIR; LENACAPAVIR SODIUM
GILD
Gilead Sciences Inc
New drug (NDA)
Type 10 - New Indication Submitted as D…
NDA220018 ↗
Apr 4, 2025LETAIRIS
AMBRISENTAN
GILD
Gilead
New drug (NDA), supplement
REMS
NDA022081 ↗
Letter or label ↗
Mar 26, 2025TRODELVY
SACITUZUMAB GOVITECAN-HZIY
GILD
Immunomedics Inc
Biologic (BLA), supplement
Labeling
BLA761115 ↗
Feb 19, 2025ODEFSEY
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENA…
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Efficacy
NDA208351 ↗
Letter or label ↗
Feb 19, 2025ODEFSEY
EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENA…
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Efficacy
NDA208351 ↗
Letter or label ↗
Jan 10, 2025VEKLURY
REMDESIVIR
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Labeling
NDA214787 ↗
Dec 23, 2024SOVALDI
SOFOSBUVIR
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Labeling
NDA212480 ↗
Dec 23, 2024SOVALDI
SOFOSBUVIR
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Labeling
NDA204671 ↗
Dec 19, 2024VEKLURY
REMDESIVIR
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Labeling
NDA214787 ↗
Dec 19, 2024HARVONI
LEDIPASVIR; SOFOSBUVIR
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Labeling
NDA212477 ↗
Dec 19, 2024LEDIPASVIR AND SOFOSBUVIR, HARVONI
LEDIPASVIR; SOFOSBUVIR
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Labeling
NDA205834 ↗
Nov 25, 2024SUNLENCA
LENACAPAVIR SODIUM
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Efficacy
NDA215974 ↗
Nov 25, 2024SUNLENCA
LENACAPAVIR SODIUM
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Efficacy
NDA215973 ↗
Nov 22, 2024TRODELVY
SACITUZUMAB GOVITECAN-HZIY
GILD
Immunomedics Inc
Biologic (BLA), supplement
Efficacy
BLA761115 ↗
Nov 13, 2024SUNLENCA
LENACAPAVIR SODIUM
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Labeling
NDA215974 ↗
Nov 13, 2024SUNLENCA
LENACAPAVIR SODIUM
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Manufacturing (CMC)
NDA215973 ↗
Oct 8, 2024BIKTARVY
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FU…
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Manufacturing (CMC)
NDA210251 ↗
Aug 19, 2024LETAIRIS
AMBRISENTAN
GILD
Gilead
New drug (NDA), supplement
REMS
NDA022081 ↗
Aug 14, 2024LIVDELZI
SELADELPAR LYSINE
GILD
Gilead Sciences Inc
New drug (NDA)
Type 1 - New Molecular Entity
NDA217899 ↗
Jul 17, 2024SUNLENCA
LENACAPAVIR SODIUM
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Labeling
NDA215974 ↗
Jul 17, 2024SUNLENCA
LENACAPAVIR SODIUM
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Labeling
NDA215973 ↗
Jun 27, 2024VEKLURY
REMDESIVIR
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Labeling
NDA214787 ↗
Apr 29, 2024TRUVADA
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
GILD
Gilead
New drug (NDA), supplement
Labeling
NDA021752 ↗
Apr 24, 2024BIKTARVY
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FU…
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Efficacy
NDA210251 ↗
Mar 27, 2024VEMLIDY
TENOFOVIR ALAFENAMIDE FUMARATE
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Efficacy
NDA208464 ↗
Mar 27, 2024VEMLIDY
TENOFOVIR ALAFENAMIDE FUMARATE
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Efficacy
NDA208464 ↗
Feb 28, 2024VEKLURY
REMDESIVIR
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Efficacy
NDA214787 ↗
Feb 23, 2024BIKTARVY
BICTEGRAVIR SODIUM; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FU…
GILD
Gilead Sciences Inc
New drug (NDA), supplement
Efficacy
NDA210251 ↗
Oct 11, 2023TRUVADA
EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE
GILD
Gilead
New drug (NDA), supplement
Manufacturing (CMC)
NDA021752 ↗

The newest 50 items, most recent first. Each row links to the FDA's page for the application, clearance or approval. Updated Nov 15, 2026, 8:18 PM EST.

Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.

Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates